ECOR - electroCore, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8200
-0.1600 (-8.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 1.9800
Open 1.9900
Bid 1.8300 x 900
Ask 2.1700 x 900
Day's Range 1.8200 - 2.0200
52 Week Range 1.4900 - 20.2500
Volume 195,437
Avg. Volume 210,878
Market Cap 53.924M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -1.3180
Earnings Date Aug 12, 2019 - Aug 16, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 18.00
Trade prices are not sourced from all markets
  • Business Wire 7 hours ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against electroCore, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of electroCore, Inc. (“electroCore” or “the Company”) (NASDAQ: ECOR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Business Wire 9 hours ago

    ECOR INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM: Announces Investigation of Securities Claims Against electroCore, Inc. - ECOR

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of electroCore, Inc. resulting from allegations that electroCore may have issued materially misleading business information to the investing public.

  • GlobeNewswire 9 days ago

    electroCore Announces Frank R. Amato to Step Down as Chief Executive Officer

    BASKING RIDGE, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive Officer in July 2016. “Under Frank’s leadership, electroCore made tremendous progress, including successfully navigating our initial public offering and transitioning to a commercial stage company with a novel technology targeting three high-value, difficult to treat headache indications,” said Carrie S. Cox, Chairman of the Board.

  • PR Newswire 20 days ago

    Lifshitz & Miller LLP Announces Investigation of A.O. Smith Corporation, Cray Inc., electroCore, Inc., Fred's Inc., Intersect ENT, Inc., Jumia Technologies AG, Lannett Company Inc., and Zayo Group Holdings, Inc.

    NEW YORK , May 30, 2019 /PRNewswire/ -- A.O. Smith Corporation (AOS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations questioning AOS' access ...

  • GlobeNewswire 21 days ago

    electroCore Announces Comprehensive Redeployment and Cost Reduction Plan

    BASKING RIDGE, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that management and the Board of Directors are making significant adjustments to the deployment of personnel and resources across the organization. The effort is intended to focus the Company on currently available and near-term revenue opportunities and on clinical programs specifically designed to expand the gammaCore™ product labeling. To achieve this goal the Company is right-sizing across its organization, including its field sales force and clinical operations.

  • Business Wire last month

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of electroCore, Inc. Investors (ECOR)

    Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. In June 2018, electroCore completed its initial public offering (“IPO”) in which it sold 5.2 million shares of its common stock at $15.00 per share.

  • GlobeNewswire last month

    Bragar Eagel & Squire, P.C. is Investigating electroCore, Inc. (NASDAQ: ECOR) on Behalf of electroCore Stockholders and Encourages electroCore Investors to Contact the Firm

    NEW YORK, May 16, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against electroCore, Inc. (NASDAQ: ECOR) on behalf of electroCore stockholders.  Our.

  • Business Wire last month

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of electroCore, Inc. Investors (ECOR)

    Law Offices of Howard G. Smith announces an investigation on behalf of electroCore, Inc.  investors concerning the Company and its officers’ possible violations of federal securities laws.

  • GlobeNewswire last month

    electroCore Announces First Quarter 2019 Financial Results

    Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities  Company to host conference call and webcast today, May 14, at 4:30pm ET.

  • GlobeNewswire last month

    electroCore to Announce First Quarter 2019 Financial Results on Tuesday, May 14

    BASKING RIDGE, N.J., May 08, 2019 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended.

  • GlobeNewswire last month

    electroCore Selected for Innovation and Technology Payment Program Through NHS England

    LONDON and BASKING RIDGE, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore, the company’s non-invasive vagus nerve stimulator (nVNS), has been selected through a highly competitive process for the Innovation and Technology Payment (ITP) Program by NHS England for use in the treatment of cluster headache in adults. Through this program, gammaCore will become a funded option for the 55,000 patients in England who suffer from cluster headache and their providers.

  • GlobeNewswire 2 months ago

    Real-World Evidence and Insights into gammaCore™ (nVNS) Mechanism of Action to be Presented at the American Academy of Neurology’s 71st Annual Meeting

    BASKING RIDGE, N.J., May 03, 2019 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that two oral presentations featuring.

  • Have Insiders Been Buying electroCore, Inc. (NASDAQ:ECOR) Shares?
    Simply Wall St. 2 months ago

    Have Insiders Been Buying electroCore, Inc. (NASDAQ:ECOR) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or s...

  • GlobeNewswire 3 months ago

    electroCore Announces Fourth Quarter and Full Year 2018 Financial Results

    BASKING RIDGE, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced fourth quarter and full year 2018 financial results and provided an operational update. “During the fourth quarter, we continued to execute on our commercial growth plan, led by our ongoing progress toward increasing covered lives through productive discussions with national and regional payers,” said Frank Amato, Chief Executive Officer of electroCore.

  • GlobeNewswire 3 months ago

    electroCore to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Wednesday, March 27

    BASKING RIDGE, N.J., March 18, 2019 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will report fourth quarter.

  • GlobeNewswire 3 months ago

    electroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™

    BASKING RIDGE, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a global commercial-stage bioelectronic medicine company, today announced new preclinical and clinical research supporting the potential therapeutic benefit of its non-invasive vagus nerve stimulator (nVNS), gammaCoreTM, for the treatment of mild traumatic brain injury (mTBI) and rheumatoid arthritis (RA). “The recent results are very encouraging as they support the broad therapeutic potential of nVNS therapy,” said Francis Amato, chief executive officer of electroCore.

  • 4 Stocks Join Ben Graham Net-Net Screener Friday
    GuruFocus.com 3 months ago

    4 Stocks Join Ben Graham Net-Net Screener Friday

    While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active

  • GlobeNewswire 3 months ago

    UPDATE - electroCore Appointments Multiple Industry Veterans to Key Management Positions

    BASKING RIDGE, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr. Tony Fiorino as chief medical officer and Brian Posner as chief financial officer. The company’s current chief medical officer, Dr. Peter Staats, will become a senior executive advisor of Medical and Government Affairs.

  • GlobeNewswire 3 months ago

    electroCore Appointments Multiple Industry Veterans to Key Management Positions

    BASKING RIDGE, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr. Tony Fiorino as chief medical officer and Brian Posner as chief financial officer. The company’s current chief medical officer, Dr. Peter Staats, will become a senior executive advisor of Medical and Government Affairs.

  • GlobeNewswire 4 months ago

    electroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark

    BASKING RIDGE, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Highmark, one of the nation’s top health insurers and the third largest Blue Cross Blue Shield affiliated company, has determined that non-implantable vagus nerve stimulation device, gammaCore, may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches.

  • GlobeNewswire 4 months ago

    electroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies

    The initiative is driven by results from an electroCore-HealthyWomen partnered survey, which showed there is a significant lack of awareness of non-drug treatment options for migraine among female patients. According to the survey of over 1,000 female migraine patients between the ages of 18 and 60 years old, 86 percent of patients are completely or somewhat willing to try non-drug treatments, however, only 36 percent expressed awareness of non-drug treatment options. To bridge this knowledge gap surrounding the availability and utility of non-drug treatment options, HealthyWomen and electroCore have developed a suite of content which can be found at HealthyWomen.org/migraine designed to educate women who suffer from migraine and to empower them to initiate a conversation with their HCP about the use of non-drug therapies in their own treatment plan.

  • ACCESSWIRE 5 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • GlobeNewswire 5 months ago

    electroCore to Present at Noble Capital Markets’ Fifteenth Annual Investor Conference

    BASKING RIDGE, N.J., Jan. 28, 2019 -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive.

  • GlobeNewswire 5 months ago

    electroCore Announces Two New Studies and a Publication Supporting the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults

    BASKING RIDGE, N.J., Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding the use of non-invasive vagus nerve stimulation (nVNS) for the acute and preventive treatment of migraine, and a recent publication of a real-world retrospective analysis which supports the use of nVNS as an effective therapeutic option for patients with cluster headache. “We are committed to expanding our knowledge of the utility of nVNS for the treatment of primary headache disorders. Through the published paper which supports the real-world effectiveness of gammaCore in cluster headache, and the initiation of two important new trials in migraine, we are continually deepening our understanding of the ability of nVNS to address unmet needs among migraine and cluster headache patients,” said Peter S. Staats, M.D., Chief Medical Officer, electroCore.

  • GlobeNewswire 6 months ago

    gammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule (FSS)

    With the FSS contract, we will deepen our commitment to the underserved patient population diagnosed with migraine or cluster headache, and are one step closer to ensuring patients who may benefit from gammaCore have access to this safe and effective therapy,” said Frank Amato, Chief Executive Officer, electroCore. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs.